Skip to main content
Mavacamten Reduces Obstructive HCM in Youth
Breaking News
Science about 3 hours ago

Mavacamten Reduces Obstructive HCM in Youth

A global clinical trial has revealed that mavacamten, a heart medication previously approved for adults, safely and effectively improves blood flow in the left ventricles of youth with hypertrophic cardiomyopathy. This groundbreaking finding, the first phase 3 trial of its kind for pediatric HCM, offers a precision medicine approach that could help many young patients avoid invasive open-heart surgery.

A global clinical trial has revealed that mavacamten, a heart medication previously approved for adults, safely and effectively improves blood flow in the left ventricles of youth with hypertrophic cardiomyopathy.

Catamist Editorial

Latest Updates

More Articles

Accessibility Options

Font Size

100%

High Contrast

Reading Preferences

Data & Privacy